

A survey of members of the European Surveillance System on Contact Allergy and the EU project “StanDerm” to identify allergens tested in cosmetic series across Europe

Emma Horton¹  | Mark Wilkinson¹  | Kristiina Aalto-Korte²  |
 Maria Pesonen²  | Andrea Bauer³  | Mahbub M.U. Chowdhury⁴ |
 Susan Cooper⁵ | Philippa Cousen⁶ | Marie-Noëlle Crépy⁷  |
 Francesca Larese Filon F⁸ | Rosella Gallo⁹  | Johannes Geier¹⁰  |
 Ana Giménez-Arnau¹¹ | Margarida Gonçalo¹²  | An Goossens¹³  |
 Cathy Green¹⁴ | Fabrizio Guarneri¹⁵ | Suzana Ljubojević Hadžavdić¹⁶  |
 Jeanne D. Johansen¹⁷  | Graham A. Johnston¹⁸ | Thomas Rustemeyer¹⁹  |
 Javier Sánchez-Pérez²⁰ | Jacob P. Thyssen²⁰ | Marie-Louise A. Schuttelaar²¹  |
 Natalie Stone²² | Wolfgang Uter²³ 

¹Department of Dermatology, Chapel Allerton Hospital, Leeds, UK

²Occupational Medicine, Finnish Institute of Occupational Health (FIOH), Helsinki, Finland

³Department of Dermatology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany

⁴Department of Dermatology, University Hospital of Wales, Cardiff, UK

⁵Department of Dermatology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

⁶Department of Dermatology, The James Cook University Hospital, Middlesbrough, UK

⁷Department of Occupational Medicine, University Hospital of Centre of Paris COCHIN, Paris, France

⁸Department of Dermatology, Dipartimento di Scienze Mediche, Chirurgiche e della Salute, Unità Operativa di Medicina del Lavoro, Università di Trieste, Trieste, Italy

⁹Department of Dermatology, Section of Dermatology, DISSAL, University of Genoa, Genoa, Italy

¹⁰Department of Dermatology, Information Network of Department of Dermatology (IVDK), Institute at the University Medical Center Goettingen, Goettingen, Germany

¹¹Department of Dermatology, Hospital del Mar, Institut Mar d'Investigacions Mediques, Universitat Autònoma, Barcelona, Spain

¹²Department of Dermatology, Clinic of Dermatology, University Hospital and Faculty of Medicine, University of Coimbra, Coimbra, Portugal

¹³Department of Dermatology, Universitair Ziekenhuis, Leuven, Belgium

¹⁴Department of Dermatology, Ninewells Hospital, Dundee, UK

¹⁵Department of Dermatology, University of Messina, Messina, Italy

¹⁶Department of Dermatology, University Department of Dermatology and Venerology, Zagreb University Hospital Center, Zagreb, Croatia

¹⁷Department of Dermatology & Allergy and National Allergy Research Centre, Herlev-Gentofte Hospital, Hellerup, Denmark

¹⁸Department of Dermatology, Leicester Royal Infirmary, Leicester, UK

¹⁹Department of Dermatology and Allergology, Amsterdam University Medical Centres, Amsterdam, The Netherlands

²⁰Dermatology Department of the Hospital de la Princesa, Madrid, Spain

²¹Department of Dermatology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

Anna Balato: University of Naples Federico II, Naples, Italy. Anna Belloni-Fortina: U.O.C. Clinica Dermatologica, Azienda Ospedaliera di Padova, Padua, Italy.

© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

²²Department of Dermatology, Royal Gwent Hospital, Newport, UK

²³Department of Medical Informatics, Biometry and Epidemiology, University of Erlangen/Nürnberg, Erlangen, Germany

Correspondence

Dr Emma Horton, Dermatology, The Leeds Teaching Hospitals NHS Trust, Leeds LS7 4SA, UK.

Email: emmahorton@nhs.net

Funding information

Horizon 2020

Abstract

Background: There is currently no agreed cosmetic series for use across Europe.

Objectives: To establish allergens currently tested in local and national cosmetic series.

Method: Members of the European Surveillance System on Contact Allergy and the European Cooperation in Science and Technology project TD1206 ("StanDerm") were surveyed to establish their current practice.

Results: A wide range of allergens was tested but there was significant variation between centres on the allergens considered to be important in screening for allergy to cosmetics. The number of allergens tested in addition to the baseline series varied between 2 and 50.

Conclusions: There is a need for further investigation to establish the frequency and relevance of reactions to cosmetic allergens to enable an agreed evidence-based cosmetic series to be produced. Criteria for inclusion need to be established.

KEYWORDS

allergic contact dermatitis, cosmetic, diagnosis

1 | INTRODUCTION

One of the main outcomes of the European Surveillance System on Contact Allergy (ESSCA) meeting in Manchester, UK in September 2016, was to develop a recommended European Cosmetic Series. As a first step, a survey was undertaken to establish which cosmetics were currently tested by members across Europe.

As European guidance on hairdressing¹ and photo-patch²/sun-screen allergens has recently been produced these were excluded. Furthermore, because of the debate over relevant screening allergens to test for fragrance allergy, this was excluded from the remit as there is currently no consensus³ and a separate ongoing debate.⁴

2 | METHODS

Members of the ESSCA and the European Cooperation on Science and Technology (COST) action TD1206 (StanDerm)⁵ project were requested to provide a list of allergens they test to exclude contact allergy to cosmetics during 2017. They were further requested to indicate if the allergens were in local or national baseline series or local or national cosmetic series. A local baseline series means allergens were screened in every patient.

3 | RESULTS

Allergens tested by country and centre are shown in Table 1. Of the 13 countries surveyed, only four (Belgium, Finland, Germany and the United Kingdom) had nationally agreed series to screen for

cosmetic allergy, among other things. Some allergens that were agreed to be cosmetic related, such as the formaldehyde releasers, were present in some national baseline series and, if not, were tested in local or national cosmetic series (eg, 23 of 26 centres tested to imidazolidinyl urea 2% pet.). At the other extreme, panthenol 5% pet was included only in the Belgian and Finnish national cosmetic series, in the local baseline series of one centre in Portugal, and in the cosmetic series of one of seven UK centres. Furthermore, the number of allergens tested above the baseline series to exclude allergy to cosmetics varied widely from two in centre Croatia 1 and 50 in United Kingdom 1.

4 | DISCUSSION

The results show a significant variation in practice throughout Europe and suggest that an evidence-based series for diagnosing allergy to cosmetics would be of value. This variation may be because the perceived importance of certain allergens varies from country to country, or it may be related to cost, or a combination of these factors. Allergens within the European baseline series typically produce a frequency of at least 0.5% to 1% allergic reactions in those tested.⁶ This includes several cosmetic related allergens that would not need retesting in a separate series, but would need to be considered as changes to the baseline series occur, and as certain allergens are considered for deletion because of the low frequency of allergic reactions.⁷

In creating a cosmetic series, the threshold for inclusion could potentially be lower, perhaps from 0.1% to 0.2% among those tested, to minimize the risk of missing a relevant contact allergy. Whilst a

TABLE 1 Allergens tested to diagnose cosmetic allergy in 26 European centres

-	E	BE1	DE1-3	DK1	ES1	FI1	FR1	HR1	IT1	IT2	IT3	IT4	IT5	NL1	NL2	PT1	RS1	SI1	UK1	UK2	UK3	UK4	UK5	UK6	UK7	No. testing
Preservative																										
Benzyl alcohol			NC 1%		C		N		C	C		C		C	C	C		C	NC	NC	NC	NC	NC	NC	NC	18
Chloroacetamide			NC		C		NC	C		C		C				C		C	NC	NC	NC	NC	NC	NC	NC	17
Disodium EDTA														C		C			NC	NC	NC	NC	NC	NC	NC	9
Di-t-butylhydroquinone			NC		C		B	C						C	B	C			NC	NC	NC	NC	NC	NC	NC	15
Ethylhexylglycerin			NC																NC	NC	NC	NC	NC	NC	NC	3
Formaldehyde	E		N 1%																							26
2-Bromo-2-nitropropane-1,3-diol		NC	NC	B	C		NC	C	B			C		B		C		C	N	N	N	N	N	N	N	20
DMDM hydantoin			NC	B	C		NC	C	B					B	B	C		C	NC	NC	NC	NC	NC	NC	NC	19
Diazolidinyl urea		NC	NC	B	C		NC	C	B	C		C	C	B	B	N		C	N	N	N	N	N	N	N	23
Imidazolidinyl urea		NC	NC	B	C		N	C	B	B	C	C	C	B	B	N		C	N	N	N	N	N	N	N	24
Quaternium 15	E		NC 2%																							26
Iodopropynyl butylcarbamate		NC	N	B	C		B	C						B	B 0.5%	B			NC	NC	NC	NC	NC	NC	NC	18
Methylchloroisothiazolinone	E																0.50%									26
Methylchloroisothiazolinone & methylisothiazolinone	E		N 0.01%														0.01%									26
Methylisothiazolinone	E		N 0.05%																							26
Sodium metabisulfite		NC	NC	C		B			B		B			B	B	C			N	N	N	N	N	N	N	18
Paraben mix*	E						NC																			26
Phenoxyethanol		NC		C	C		C				C			B		C		B	B		C					9
Potassium sorbate				B										C				B								3
Sodium benzoate			NC 2%	C			C					C			C	C		B	B				C			10
Sorbic acid		NC	NC	B	C					C	C	C				C		NC	NC	NC	NC	NC	NC	NC	NC	16
p-Chloro-m-cresol				C	C		B		C			C				C		N	N	N	N	N	N	N	N	13
Antimicrobial																										
Benzalkonium chloride							NC	N	C		C		C	B			C	C								7
Chloroxenol					C		C		C		C		C			C		N	N	N	N	N	N	N	N	12
Chlorhexidine diacetate				B													C	C								3
Chlorhexidine digluconate			NC	B	C		N	C	C			C				B		C	C		C					12
Triclosan			NC		C		NC	C			C	C	C			C		NC	NC	NC	NC	NC	NC	NC	NC	16
Antioxidant																										
BHA (butylated hydroxyanisole)			NC		C		C		C	C		C		C	C	C		NC	NC	NC	NC	NC	NC	NC	NC	18
BHT (butylated hydroxytoluene)			NC		C		B	C	C	C	C	C		C	C	C		NC	NC	NC	NC	NC	NC	NC	NC	20
Caprylyl gallate			NC																							3
Propyl gallate		NC		C	C						C	C	C**			C		NC	NC	NC	NC	NC	NC	NC	NC	14
Tocopheryl acetate				C	C													C				C				5

(Continues)

TABLE 1 (Continued)

-																					No. testing					
Emollient																					UK7					
Lanolin alcohols	30% pet.	E																			26					
Lanolin	"as is"																				5					
Amerchol L101	50% pet.	N	NC	C	C		N								B	B	B			NC	NC	NC	NC	NC	NC	17
Cetearyl alcohol	20% pet.	NC	N	C	C	NC	C		C	§	C	30%			C	C5%	C			N	N	N	N	N	N	22
Panthenol (Dexpanthenol)	5% pet.	NC				NC											B			C					4	
Propolis	10% pet.		N			NC	C		C	C	B		C		C	C	C			C	NC	NC	NC	NC	NC	20
Emulsifier/surfactants																					UK7					
Polysorbate 80	5% pet.																									7
Sorbitan sesquioleate	20% pet.		N	C	C	NC	C		B	¶	B				B	C				NC	NC	NC	NC	NC	NC	19
Cocamide DEA	0.5% pet.	C				NC	N										C			NC	NC	NC	NC	NC	NC	15
Cocamidopropyl betaine	1% aq.	NC	NC	C	C	C	B				B		C		C	C	C			C	NC	NC	NC	NC	NC	20
Dimethylaminopropylamine (Mono)Ethanolamine	1% pet.	NC				C	B	N							C					C			C			9
	2% pet.						B													C						3
Oleamidopropyl dimethylamine	0.1% aq.					C	B	C					C		C	C	C			NC	NC	NC	NC	NC	NC	14
Triethanolamine (Trolamine)	2% pet.		NC	2.5%	C	C		C					C		C	2.5%	C			NC	NC	NC	NC	NC	NC	18
Caprylyl/Capryl glucoside	10% aq.																			C						1
Cetearyl glucoside	10% pet.																			C						1
Coco-glucoside	10% aq.																			C						2
Decyl glucoside	5% pet./10% aq.	NC				C	C	C					C		C					C					C	8
Lauryl glucoside	3% pet./10% aq.	NC				C	C	N							C		C			C	C		C		C	9
Solvent/vehicle																					UK7					
Propylene glycol	20% aq.		NC			C	C													C		B	C			15
Specific function																					UK7					
axilla																					UK7					
Aluminium hydroxide	10% pet.																			C	C					3
Face, eye & lip																					UK7					
Colophonium	20% pet.	E																								26
Abitol	10% pet.					C		C												NC	NC	NC	NC	NC	NC	9
Retinyl palmitate (Vitamin A ester)	0.5% pet.																			C						2
Shellac	20% EtOH					C		C												C		C				5
Nail																					UK7					
Tosylamide/ formaldehyde resin	10% pet.	N					N	C												NC	NC	NC	NC	NC	NC	16
Adipic acid/neopentyl glycol/trimellitic anhydride copolymer	1% pet.																			C			B	C	C	4

(Continues)

TABLE 1 (Continued)

	E	BE1	DE1-3	DK1	ES1	FI1	FR1	HR1	IT1	IT2	IT3	IT4	IT5	NL1	NL2	PT1	RS1	SI1	UK1	UK2	UK3	UK4	UK5	UK6	UK7	No. testing
Phthalic anhydride/trimellitic anhydride/glycols copolymer									C					C					C		B	C	C	C		6
2-Hydroxyethyl methacrylate				B		B	B	B	C	N		N		C		N		C	B		B			B		12
Hydroquinone			NC																							3

Note: Allergens in the European baseline are tested in all centres with variations being shown in the relevant column.

Abbreviations: aq., aqueous; B, local baseline series (allergens screened in every patient); BE, Belgium; C, local cosmetic series; DE, Germany; DK, Denmark; E, European baseline; ES, Spain; ETOH, ethanol; FI, Finland; FR, France; HR, Croatia; IT, Italy; N, national baseline series; NC, national cosmetic series; NL, The Netherlands; pet., petrolatum; PT, Portugal; RS, Serbia; SI, Slovenia; UK, United Kingdom.

*Methylparaben, ethylparaben, propylparaben, butylparaben.

**Gallate mix 1.5% pet.

§Cetyl alcohol 5% pet. & stearyl alcohol 30% pet.

¶Sorbitan oleate 5% pet.

patient's own products should also be tested where a reaction is suspected, these frequently produce false-negative reactions due to the lower concentration in the product and, therefore, would not provide a perfect fail-safe.

Current European Union regulations define a cosmetic broadly as "any preparation that is intended to be rubbed, poured, sprinkled or sprayed on, introduced into or otherwise applied to the human body or any part thereof for cleansing, beautifying, promoting attractiveness or altering the physical appearance." Consequently, creating a cosmetic series potentially lends itself to a modular construction where the final sequence of allergens tested is based on the varying exposures of the patient (eg, hairdressing,¹ sunscreen² or fragrance).⁴ This is the approach taken in the Information Network of Departments of Dermatology (IVDK), where allergens tested are derived from the combination of two smaller series. In particular, many medicaments contain allergens that are common with cosmetics. A common series containing preservatives, antioxidants, and emollient ingredients may, therefore, be of value for both cosmetic and medicament exposures. Conversely, antimicrobials, such as chlorhexidine, that are associated more commonly with medicaments may also be relevant in the context of cosmetic allergy⁸ whilst allergens such as tosylamide/formaldehyde resin or phthalic anhydride/trimellitic anhydride/glycols copolymer⁹ are purely cosmetic in the specific context of nail varnish.

At present, the frequency and relevance of reactions to these additional cosmetic allergens across Europe is not known. Collation of results is essential to enable a recommended evidence-based cosmetic series to be produced. While some countries¹⁰ have published data, there is a need for a greater geographical spread and testing to a wider range of allergens to enable guidance to be produced. A recent study from the UK¹¹ highlighted that eight allergens tested in the cosmetic series of one centre produced no relevant reactions over an 8-year period. This led to a national review which resulted in 11 allergens being removed from the British group's facial series and the addition of eight others found to be relevant, but not tested by many.¹²

The significant variations in practice throughout Europe might not only be due to a lack of standardization but also due to different exposure profiles. A European cosmetic series should take this into account. After analysis of the country-specific data, a core European cosmetic series could be established and supplemented by a national "extension" cosmetic series dependent on local exposure. In conclusion, there is a need to develop an evidence-based cosmetic series to improve and standardize diagnosis and at the same time, eliminate allergens with a poor yield to ensure that the test is cost effective.

ACKNOWLEDGEMENT

This study was supported in part by the Horizon 2020 COST action TD 1206 "StanDerm".

CONFLICTS OF INTEREST

The IVDK, of which JG is an employee, is sponsored by the cosmetics and fragrance industries (associations) as well as by public funds; WU:

accepted travel reimbursement and partly honoraria for presentations given to cosmetic industry associations and received a lecture fee from mixed dermato-pharmaceutical sponsors for an educational lecture on contact allergy; SMW: accepted travel reimbursement to attend meetings with the cosmetics industry; The other authors do not declare any conflict of interest.

ORCID

Emma Horton  <https://orcid.org/0000-0002-4092-4246>

Mark Wilkinson  <https://orcid.org/0000-0001-7253-3461>

Kristiina Aalto-Korte  <https://orcid.org/0000-0002-5595-5512>

Maria Pesonen  <https://orcid.org/0000-0003-0356-7064>

Andrea Bauer  <https://orcid.org/0000-0002-4411-3088>

Marie-Noëlle Crépy  <https://orcid.org/0000-0002-9824-1034>

Rosella Gallo  <https://orcid.org/0000-0002-1735-4425>

Johannes Geier  <https://orcid.org/0000-0002-5047-8948>

Margarida Gonçalves  <https://orcid.org/0000-0001-6842-1360>

An Goossens  <https://orcid.org/0000-0002-9805-3439>

Suzana Ljubojević Hadžavdić  <https://orcid.org/0000-0002-3640-9567>

Jeanne D. Johansen  <https://orcid.org/0000-0002-3537-8463>

Thomas Rustemeyer  <https://orcid.org/0000-0001-7580-0684>

Marie-Louise A. Schuttelaar  <https://orcid.org/0000-0002-0766-4382>

Wolfgang Uter  <https://orcid.org/0000-0002-4498-3710>

REFERENCES

1. Uter W, Bensefa-Colas L, Frosch P, et al. Patch testing with hair cosmetic series in Europe: a critical review and recommendation. *Contact Dermatitis*. 2015;73(2):69-81.
2. Gonçalves M, Ferguson J, Bonevalle A, et al.; The European Multicentre Photopatch Test Study (EMCPPTS) Taskforce. Photopatch testing: recommendations for a European photopatch test baseline series. *Contact Dermatitis*. 2013;68(4):239-243.
3. Wilkinson M, Gonçalves M, Aerts O, et al. The European baseline series and recommended additions: 2019. *Contact Dermatitis*. 2019;80(1):1-4.
4. Bennike NH, Zachariae C, Johansen JD. Non-mix fragrances are top sensitizers in consecutive dermatitis patients - a cross-sectional study of the 26 EU-labelled fragrance allergens. *Contact Dermatitis*. 2017;77(5):270-279.
5. COST TD1206. European Cooperation in Science and Technology. <https://www.cost.eu/actions/TD1206/#tabs|Name:overview>. Accessed September 7, 2019.
6. Bruze M, Condé-Salazar L, Goossens A, et al. Thoughts on sensitizers in a standard patch test series. The European Society of Contact Dermatitis. *Contact Dermatitis*. 1999;41(5):241-250.
7. Fransway AF, Fransway PJ, Belsito DV, et al. Parabens. *Dermatitis*. 2019;30(1):3-31.
8. Opstrup MS, Johansen JD, Zachariae C, Garvey LH. Contact allergy to chlorhexidine in a tertiary dermatology clinic in Denmark. *Contact Dermatitis*. 2016;74(1):29-36.
9. Gach JE, Stone NM, Finch TM. A series of four cases of allergic contact dermatitis to phthalic anhydride/trimellitic anhydride/glycols copolymer in nail varnish. *Contact Dermatitis*. 2005;53(1):63-64.
10. Dinkloh A, Worm M, Geier J, Schnuch A, Wollenberg A. Contact sensitization in patients with suspected cosmetic intolerance: results of the IVDK 2006-2011. *J Eur Acad Dermatol Venereol*. 2015;29(6):1071-1081.
11. Owen E, Chowdhury MMU. The cosmetic series 8 years' review: what's in, what's out? *Contact Dermatitis*. 2016;79(Suppl 1):92.
12. Rolls S, Owen E, Bertram C, et al. What's in? What's out? Giving the British Society of Cutaneous Allergy facial series a lift. *Br J Dermatol*. 2019;181(Suppl 1):156.

How to cite this article: Horton E, Wilkinson M, Aalto-Korte K, et al. A survey of members of the European Surveillance System on Contact Allergy and the EU project "StanDerm" to identify allergens tested in cosmetic series across Europe. *Contact Dermatitis*. 2020;82:195-200. <https://doi.org/10.1111/cod.13437>